>亚太活性药物成分 (API) 市场，按分子（小分子、大分子）、类型（创新活性药物成分、通用创新活性药物成分）、制造商类型（专属 API 制造商、商业 API 制造商）、合成（合成活性药物成分和生物技术活性药物成分）、化学合成（对乙酰氨基酚、青蒿素、沙格列汀、氯化钠、布洛芬、氯沙坦钾、依诺肝素钠、卢非酰胺、萘普生、他莫昔芬、其他）、药物类型（处方药、非处方药）、用途（临床、研究）、效力（低至中等效力活性药物成分、强效至高效活性药物成分）、治疗应用（心脏病学、中枢神经系统和神经病学、肿瘤学、骨科、内分泌学、肺病学、胃肠病学、肾病学、眼科、其他治疗应用）、国家（日本、中国、澳大利亚、印度、韩国、新加坡、印度尼西亚、泰国、马来西亚、菲律宾、越南、亚太地区其他地区）行业趋势及预测至 2028 年
市场分析和见解：亚太地区活性药物成分 (API) 市场
预计活性药物成分 (API) 市场将在 2021 年至 2028 年的预测期内实现市场增长。Data Bridge Market Research 分析，在 2021 年至 2028 年的预测期内，该市场的复合年增长率为 7.5%，预计到 2028 年将达到 86,222.48 亿美元。各种慢性疾病患病率的增加和老龄化人口的增加是推动预测期内活性药物成分 (API) 市场需求的主要驱动因素。
- 在希腊语中，活性药物成分 (API) 的传统单词是 pharmacon 或 pharmakon，象征着一种神奇的物质或药物。ICH Q7 中描述的活性药物成分是“任何用于制造药品的物质或物质组合，当用于生产药品时，它们将成为活性药物成分。此类物质用于提供药理活性。
技术进步的增加将增强市场参与者的能力和制造技能，制造商必须批量提供 API 并满足消费者的需求，从而推动活性药物成分 (API) 市场的增长。劣质药品和假药的出现阻碍了活性药物成分 (API) 市场的需求。对 API 开发研究的投资增加将进一步增加活性药物成分 (API) 市场的增长机会。COVID-19 期间 API 供应链中断对医疗保健提供商构成挑战，这可能会对活性药物成分 (API) 市场构成挑战。
活性药物成分 (API) 市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息，分析了新兴收入领域、市场法规变化、产品批准、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情况，请联系我们获取分析师简报，我们的团队将帮助您创建收入影响解决方案，以实现您的期望目标。
亚太地区活性药物成分 (API) 市场范围和市场规模
活性药物成分 (API) 市场根据分子、类型、制造商类型、合成、化学合成、药物类型、用途、效力和治疗应用进行细分。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
- 根据分子，活性药物成分 (API) 市场分为小分子和大分子。2021 年，由于监管部门批准数量不断增加，且新型小分子因其高渗透力而研发不断增加，预计小分子将主导活性药物成分 (API) 市场。
- 根据类型，活性药物成分 (API) 市场分为创新活性药物成分和仿制活性药物成分。2021 年，创新活性药物成分市场预计将主导活性药物成分 (API) 市场，因为创新 API 的成本高于仿制 API，而且 FDA 对新分子实体的批准不断增加。
- 根据制造商类型，活性药物成分 (API) 市场分为专属 API 制造商和商业 API 制造商。2021 年，专属 API 制造商细分市场预计将主导活性药物成分 (API) 市场，因为主要市场参与者投入巨资来建设高端制造设施并轻松获得原材料。
- 根据合成方式，活性药物成分 (API) 市场可分为合成活性药物成分和生物技术活性药物成分。2021 年，合成活性药物成分市场预计将占据活性药物成分 (API) 市场的主导地位，因为合成分子的方案简单、监管准则不太严格，而且未来几年，许多合成分子的专利将到期。
- 根据化学合成，活性药物成分 (API) 市场细分为对乙酰氨基酚、青蒿素、沙格列汀、氯化钠、布洛芬氯沙坦钾、依诺肝素钠、卢非酰胺、萘普生、他莫昔芬等。2021 年，由于 API 成本高昂且全球糖尿病病例不断增加，预计沙格列汀将主导活性药物成分 (API) 市场。
- 根据药物类型，活性药物成分 (API) 市场分为处方药和非处方药。2021 年，处方药市场占据活性药物成分 (API) 市场的主导地位，因为药物成本高，这将增加 API 和 API 的制造成本。
- 根据用途，活性药物成分 (API) 市场分为临床和研究。2021 年，由于需要持续供应 API 和原材料的疾病数量不断增加，预计临床领域将主导活性药物成分 (API) 市场。
- 根据效力，活性药物成分 (API) 市场分为低至中等效力活性药物成分和强效至高效活性药物成分。2021 年，低至中等效力活性药物成分部分预计将主导活性药物成分 (API) 市场，因为它们毒性较小且危害性较小。
- 根据治疗应用，活性药物成分 (API) 市场细分为心脏病学、中枢神经系统和神经病学、肿瘤学、骨科、内分泌学、肺病学、胃肠病学、肾病学、眼科学和其他治疗应用。2021 年，心脏病学领域预计将主导活性药物成分 (API) 市场，因为心脏病发作、栓塞等心脏疾病的数量不断增加。
活性药物成分 (API) 市场国家层面分析
对活性药物成分 (API) 市场进行分析，并根据上述国家、分子、类型、制造商类型、合成、化学合成、药物类型、用途、效力和治疗应用提供市场规模信息。
亚太活性药物成分 (API) 市场报告涵盖的国家包括日本、中国、澳大利亚、印度、韩国、新加坡、印度尼西亚、泰国、马来西亚、菲律宾、越南和亚太其他地区。
由于政府大力推动原料药 (API) 生产，中国在亚太地区原料药 (API) 市场占据主导地位。
报告的国家部分还提供了影响单个市场因素和国内市场法规变化，这些变化影响了市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了亚太品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战、销售渠道的影响。
各种慢性疾病的患病率不断上升，推动了活性药物成分 (API) 市场的增长
活性药物成分 (API) 市场还为您提供每个国家/地区活性药物成分 (API) 行业增长的详细市场分析，包括活性药物成分 (API) 药物销售、活性药物成分 (API) 技术进步的影响以及监管环境的变化及其对活性药物成分 (API) 市场的支持。数据涵盖 2010 年至 2019 年的历史时期。
竞争格局和活性药物成分 (API) 市场份额分析
活性药物成分 (API) 市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对活性药物成分 (API) 市场的关注有关。
从事活性药物成分 (API) 经营的主要公司包括 Dr. Reddy's Laboratories Ltd.、Sun Pharmaceutical Industries Ltd.、Pfizer Inc.、Sanofi、GlaxoSmithKline plc.、Aarti Industries Limited、Recipharm AB、Jubilant Pharmova Limited、LUPIN、Aurobindo Pharma、、AbbVie Inc.、AstraZeneca、Alkem Labs、Albemarle Corporation、Saneca Pharmaceuticals、Unichem Laboratories、Neuland Laboratories Ltd.、Divi's Laboratories Limited.、HIKAL Ltd.、Viatris Inc.、Merck KGaA、Novo Nordisk A/S、Sandoz International GmbH、Teva Pharmaceutical Industries Ltd.、BASF SE、Piramal Pharma Solutions 等。DBMR 分析师了解竞争优势并为每个竞争对手分别提供竞争分析。
全球范围内的许多产品发布和协议也由公司发起，这也加速了活性药物成分（API）市场的发展。
例如，
- 2019 年 12 月，AbbVie Inc. 与 Scripps Research 合作，以加强针对一系列疾病（包括肿瘤学、免疫学等领域）的新药研发。根据合作协议，Scripps Research 将开展临床前研究活动，以开发新疗法。此次合作帮助该公司为患者开发新药，最终提高了公司的收入。
市场参与者的合作、产品发布、业务扩展、奖励和认可、合资企业和其他策略正在增强公司在活性药物成分 (API) 市场中的市场，这也为组织改进其对活性药物成分 (API) 的供应提供了好处。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 MOLECULE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET TYPE OF MANUFACTURER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS: COUNTRIES WITH DATA OF IMPORTS AND EXPORTS
4.2 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS: COLOMBIA DATA OF THE ORIGIN COUNTRY OF THE IMPORTS
4.3 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS: COLOMBIA DATA OF THE IMPORTS AND EXPORTS BY MOLECULES IN VALUES AND VOLUMES
5 PIPELINE ANALYSIS
6 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: REGULATORY FRAMEWORK
6.1 CURRENT GOODS MANUFACTURING PRACTICES
6.2 REGULATORY REQUIREMENTS FOR REGISTRATION OF API IN THE U.S. AND EU
6.3 REGISTRATION OF API IN THE U.S.
6.4 REGISTRATION OF API IN EUROPE
6.5 REGULATORY REQUIREMENTS IN INDIA
6.6 REGULATORY FRAMEWORK IN CHINA
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF VARIOUS CHRONIC DISORDERS
7.1.2 INCREASE IN AGING POPULATION
7.1.3 UTILIZATION OF ADVANCED TECHNOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURING
7.1.4 INCREASING DISEASE AWARENESS AND EDUCATION
7.1.5 PATENT EXPIRY OF BRANDED ACTIVE PHARMACEUTICAL INGREDIENTS (API)
7.2 RESTRAINTS
7.2.1 AVAILABILITY OF SUB-STANDARD AND COUNTERFEIT DRUGS
7.2.2 HIGH MANUFACTURING COST
7.2.3 ADVERSE HEALTH EFFECTS OF EXPOSURE TO ACTIVE PHARMACEUTICAL INGREDIENTS (API)
7.3 OPPORTUNITIES
7.3.1 COLLABORATION AND ACQUISITION AMONG THE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURERS
7.3.2 INCREASING HEALTHCARE EXPENDITURE
7.3.3 RISING INVESTMENT IN RESEARCH REGARDING THE DEVELOPMENT OF ACTIVE PHARMACEUTICAL INGREDIENTS (API)
7.3.4 SOARING NUMBER OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURERS
7.4 CHALLENGES
7.4.1 DISRUPTION IN THE SUPPLY CHAIN OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) DURING COVID-19
7.4.2 LACK OF WORKFORCE IN PHARMA INDUSTRIES
7.4.3 PRODUCT RECALLS
8 IMPACT OF COVID 19 PANDEMIC ON THE ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET
8.1 PRICE IMPACT
8.2 IMPACT ON SUPPLY CHAIN
8.3 IMPACT ON DEMAND
8.4 STRATEGIC DECISIONS FOR MANUFACTURERS
8.5 CONCLUSION
9 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE
9.1 OVERVIEW
9.2 SMALL MOLECULE
9.3 LARGE MOLECULE
10 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE
10.1 OVERVIEW
10.2 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
10.3 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
11 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER
11.1 OVERVIEW
11.2 CAPTIVE API MANUFACTURERS
11.3 MERCHANT API MANUFACTURERS
11.3.1 TYPE
11.3.1.1 Merchant Innovative API Manufacturers
11.3.1.2 Merchant Generic API Manufacturers
11.3.2 TYPE OF SYNTHESIS
11.3.2.1 Merchant Synthetic API Manufacturers
11.3.2.2 Merchant Biotech API Manufacturers
12 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS
12.1 OVERVIEW
12.2 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENT
12.2.1 INNOVATIVE SYNTHETIC APIS
12.2.2 GENERIC SYNTHETIC APIS
12.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT
12.3.1 TYPE
12.3.1.1 Innovative Biotech APIs
12.3.1.2 Generic Biotech APIs
12.3.2 PRODUCT
12.3.2.1 Monoclonal Antibodies
12.3.2.2 Adalimumab
12.3.2.3 Ustekinumab
12.3.2.4 Secukinumab
12.3.2.5 Cetuximab
12.3.2.6 Daclizumab
12.3.2.7 Omalizumab
12.3.2.8 Vedolizumab
12.3.2.9 Abciximab
12.3.2.10 Efalizumab
12.3.2.11 Others
12.3.2.2 Cytokines
12.3.2.2.1 Interleukin-2
12.3.2.2.2 Interferon Beta-1A
12.3.2.2.3 Interleukin-10
12.3.2.2.4 Interleukin-9
12.3.2.2.5 Erythropoietin
12.3.2.2.6 Others
12.3.2.3 Hormones & Growth Factors
12.3.2.4 Blood Factors
12.3.2.5 Recombinant Vaccines
12.3.2.6 Therapeutic Enzymes
12.3.3 EXPRESSION SYSTEM
12.3.3.1 Mammalian Expression System
12.3.3.2 Yeast Expression System
12.3.3.3 Microbial Expression System
12.3.3.4 Insect Expression System
12.3.3.5 Others Expression System
13 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS
13.1 OVERVIEW
13.2 SAXAGLIPTIN
13.3 ENOXAPARIN SODIUM
13.4 RUFINAMIDE
13.5 TAMOXIFEN
13.6 ARTEMISININ
13.7 LOSARTAN POTASSIUM
13.8 NAPROXEN
13.9 IBUPROFEN
13.1 ACETAMINOPHEN
13.11 SODIUM CHLORIDE
13.12 OTHERS
14 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG
14.1 OVERVIEW
14.2 PRESCRIPTION DRUGS
14.3 OVER-THE-COUNTER
15 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE
15.1 OVERVIEW
15.2 CLINICAL
15.3 RESEARCH
16 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY
16.1 OVERVIEW
16.2 LOW-TO-MODERATE POTENT ACTIVE PHARMACEUTICAL INGREDIENT
16.3 POTENT-TO-HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENT
17 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION
17.1 OVERVIEW
17.2 CARDIOLOGY
17.2.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
17.2.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
17.3 CNS & NEUROLOGY
17.3.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
17.3.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
17.4 ONCOLOGY
17.4.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
17.4.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
17.5 GASTROENTEROLOGY
17.5.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
17.5.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
17.6 PULMONOLOGY
17.6.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
17.6.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
17.7 ENDOCRINOLOGY
17.7.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
17.7.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
17.8 NEPHROLOGY
17.8.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
17.8.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
17.9 ORTHOPEDIC
17.9.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
17.9.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
17.1 OPHTHALMOLOGY
17.10.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
17.10.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
17.11 OTHERS
17.11.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
17.11.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
18 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY REGION
18.1 ASIA-PACIFIC
18.1.1 CHINA
18.1.2 INDIA
18.1.3 JAPAN
18.1.4 AUSTRALIA
18.1.5 SOUTH KOREA
18.1.6 SINGAPORE
18.1.7 MALAYSIA
18.1.8 THAILAND
18.1.9 INDONESIA
18.1.10 PHILIPPINES
18.1.11 VIETNAM
18.1.12 REST OF ASIA-PACIFIC
19 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
20 SWOT ANALYSIS
21 COMPANY PROFILE
21.1 TEVA PHARMECEUTICALS INDUSTRIES LTD.
21.1.1 COMPANY SNAPSHOT
21.1.2 RECENT FINANCIALS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENT
21.2 PFIZER, INC.
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMPANY SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 SANOFI
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE ANALYSIS
21.3.3 COMPANY SHARE ANALYSIS
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENTS
21.4 MERCK KGAA
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 COMPANY SHARE ANALYSIS
21.4.4 PRODUCT PORTFOLIO
21.4.5 RECENT DEVELOPMENT
21.5 SANDOZ INTERNATIONAL GMBH (A SUBSIDIARY OF NOVARTIS AG)
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 PRODUCT PORTFOLIO
21.5.4 RECENT DEVELOPMENT
21.6 AUROBINDO PHARMA
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANALYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENT
21.7 ALBEMARLE CORPORATION
21.7.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENTS
21.8 ASTRAZENECA
21.8.1 COMPANY SNAPSHOT
21.8.2 REVENUE ANALYSIS
21.8.3 PRODUCT PORTFOLIO
21.8.4 RECENT DEVELOPMENT
21.9 DIVI’S LABORATORIES LIMITED
21.9.1 COMPANY SNAPSHOT
21.9.2 REVENUE ANALYSIS
21.9.3 PRODUCT PORTFOLIO
21.9.4 RECENT DEVELOPMENTS
21.1 DR. REDDY’S LABORATORY LTD.
21.10.1 COMPANY SNAPSHOT
21.10.2 RECENT FINANCIALS
21.10.3 PRODUCT PORTFOLIO
21.10.4 RECENT DEVELOPMENT
21.11 PIRAMAL PHARMA SOLUTIONS
21.11.1 COMPANY SNAPSHOT
21.11.2 PRODUCT PORTFOLIO
21.11.3 RECENT DEVELOPMENTS
21.12 AARTI INDUSTRIES LIMITED
21.12.1 COMPANY SNAPSHOT
21.12.2 REVENUE ANALYSIS
21.12.3 PRODUCT PORTFOLIO
21.12.4 RECENT DEVELOPMENT
21.13 ABBVIE INC
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENTS
21.14 ALKEM LABS
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENTS
21.15 ALEMBIC PHARMACEUTICALS LIMITED
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENTS
21.16 BASF SE
21.16.1 COMPANY SNAPSHOT
21.16.2 RECENT FINANCIALS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT DEVELOPMENT
21.17 CIPLA INC.
21.17.1 COMPANY SNAPSHOT
21.17.2 RECENT FINANCIALS
21.17.3 PRODUCT PORTFOLIO
21.17.4 RECENT DEVELOPMENTS
21.18 CORDENPHARMA INTERNATIONAL
21.18.1 COMPANY SNAPSHOT
21.18.2 PRODUCT PORTFOLIO
21.18.3 RECENT DEVELOPMENTS
21.19 GLAXOSMITHKLINE PLC
21.19.1 COMPANY SNAPSHOT
21.19.2 REVENUE FINANCIALS
21.19.3 PRODUCT PORTFOLIO
21.19.4 RECENT DEVELOPMENT
21.2 HIKAL LTD.
21.20.1 COMPANY SNAPSHOT
21.20.2 REVENUE ANALYSIS
21.20.3 PRODUCT PORTFOLIO
21.20.4 RECENT DEVELOPMENTS
21.21 JUBILANT LIFE SCIENCES LIMITED
21.21.1 COMPANY SNAPSHOT
21.21.2 REVENUE ANALYSIS
21.21.3 PRODUCT PORTFOLIO
21.21.4 RECENT DEVELOPMENT
21.22 LUPIN
21.22.1 COMPANY SNAPSHOT
21.22.2 REVENUE ANALYSIS
21.22.3 PRODUCT PORTFOLIO
21.22.4 RECENT DEVELOPMENTS
21.23 MINAKIM
21.23.1 COMPANY SNAPSHOT
21.23.2 PRODUCT PORTFOLIO
21.23.3 RECENT DEVELOPMENTS
21.24 NEULAND LABORATORIES LTD.
21.24.1 COMPANY SNAPSHOT
21.24.2 REVENUE ANALYSIS
21.24.3 PRODUCT PORTFOLIO
21.24.4 RECENT DEVELOPMENTS
21.25 NOVO NORDISK A/S
21.25.1 COMPANY SNAPSHOT
21.25.2 REVENUE ANALYSIS
21.25.3 PRODUCT PORTFOLIO
21.25.4 RECENT DEVELOPMENT
21.26 RECIPHARM AB
21.26.1 COMPANY SNAPSHOT
21.26.2 REVENUE ANALYSIS
21.26.3 PRODUCT PORTFOLIO
21.26.4 RECENT DEVELOPMENTS
21.27 SANECA PHARMACEUTICALS
21.27.1 COMPANY SNAPSHOT
21.27.2 PRODUCT PORTFOLIO
21.27.3 RECENT DEVELOPMENTS
21.28 SUN PHARMACEUTICAL INDUSTRIES LTD.
21.28.1 COMPANY SNAPSHOT
21.28.2 REVENUE ANALYSIS
21.28.3 PRODUCT PORTFOLIO
21.28.4 RECENT DEVELOPMENTS
21.29 UNICHEM LABORATORIES
21.29.1 COMPANY SNAPSHOT
21.29.2 REVENUE ANALYSIS
21.29.3 PRODUCT PORTFOLIO
21.29.4 RECENT DEVELOPMENTS
21.3 VIATRIS INC.
21.30.1 COMPANY SNAPSHOT
21.30.2 PRODUCT PORTFOLIO
21.30.3 RECENT DEVELOPMENTS
22 QUESTIONNAIRE
23 RELATED REPORTS
表格列表
TABLE 1 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, PIPELINE ANALYSIS
TABLE 2 DIFFERENCE BETWEEN THE U.S. AND EU FOR THE REGISTRATION PROCESS
TABLE 3 DIFFERENCE BETWEEN THE U.S. AND EU FOR THE ADMINISTRATIVE REQUIREMENTS
TABLE 4 AGE DISTRIBUTION OF THE U.K. POPULATION (FROM 1976 TO 2046)
TABLE 5 WORLD –WIDE IMPACT OF COVID-19 ON THE PHARMACEUTICAL SECTOR
TABLE 6 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 7 ASIA-PACIFIC SMALL MOLECULE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 8 ASIA-PACIFIC LARGE MOLECULE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 9 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 10 ASIA-PACIFIC INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC GENERIC ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 12 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURERS, 2017-2028 (USD MILLION)
TABLE 13 ASIA-PACIFIC CAPTIVE API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 14 ASIA-PACIFIC MERCHANT API MANUFACTURER IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET , BY REGION, 2017-2028 (USD MILLION)
TABLE 15 ASIA-PACIFIC TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 16 ASIA-PACIFIC TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 17 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 18 ASIA-PACIFIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 19 ASIA-PACIFIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 20 ASIA-PACIFIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 21 ASIA-PACIFIC TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 22 ASIA-PACIFIC PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 23 ASIA-PACIFIC MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 24 ASIA-PACIFIC CYTOKINESPRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 25 ASIA-PACIFIC EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 26 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2019-2028 (USD MILLION)
TABLE 27 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2019-2028 (UNITS)
TABLE 28 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2019-2028 (ASP)
TABLE 29 ASIA-PACIFIC SAXAGLIPTIN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, REGION, 2017-2028 (USD MILLION)
TABLE 30 ASIA-PACIFIC ENOXAPARIN SODIUM IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 31 ASIA-PACIFIC RUFINAMIDE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 32 ASIA-PACIFIC TAMOXIFEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 33 ASIA-PACIFIC ARTEMISININ IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 34 ASIA-PACIFIC LOSARTAN POTASSIUM IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 35 ASIA-PACIFIC NAPROXEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 36 ASIA-PACIFIC IBUPROFEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 37 ASIA-PACIFIC ACETAMINOPHEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 38 ASIA-PACIFIC SODIUM CHLORIDE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 39 ASIA-PACIFIC OTHERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 40 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2019-2028 (USD MILLION)
TABLE 41 ASIA-PACIFIC PRESCRIPTION DRUGS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 42 ASIA-PACIFIC OVER-THE-COUNTER IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 43 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 44 ASIA-PACIFIC CLINICAL IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 45 ASIA-PACIFIC OVER-THE-COUNTER IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 46 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 47 ASIA-PACIFIC LOW-TO-MODERATE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 48 ASIA-PACIFIC POTENT-TO-HIGHLY POTENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 49 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 50 ASIA-PACIFIC CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 51 ASIA-PACIFIC CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 52 ASIA-PACIFIC CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 53 ASIA-PACIFIC CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 54 ASIA-PACIFIC ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 55 ASIA-PACIFIC ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 56 ASIA-PACIFIC GASTROENTEROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 57 ASIA-PACIFIC GASTROENTEROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 58 ASIA-PACIFIC PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 59 ASIA-PACIFIC PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 60 ASIA-PACIFIC ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 61 ASIA-PACIFIC ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 62 ASIA-PACIFIC NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 63 ASIA-PACIFIC NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 64 ASIA-PACIFIC ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 65 ASIA-PACIFIC ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 66 ASIA-PACIFIC OPHTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 67 ASIA-PACIFIC OPHTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 68 ASIA-PACIFIC OTHERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 69 ASIA-PACIFIC OTHERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 70 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY COUNTRY, 2018-2028 (USD MILLION)
TABLE 71 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 72 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 73 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 74 ASIA-PACIFIC TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 75 ASIA-PACIFIC TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 76 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 77 ASIA-PACIFIC SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 78 ASIA-PACIFIC TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 79 ASIA-PACIFIC PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 80 ASIA-PACIFIC MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 81 ASIA-PACIFIC CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 82 ASIA-PACIFIC EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 83 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 84 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 85 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 86 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 87 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 88 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 89 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 90 ASIA-PACIFIC CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 91 ASIA-PACIFIC CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 92 ASIA-PACIFIC ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 93 ASIA-PACIFIC GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 94 ASIA-PACIFIC PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 95 ASIA-PACIFIC ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 96 ASIA-PACIFIC NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 97 ASIA-PACIFIC ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 98 ASIA-PACIFIC OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 99 ASIA-PACIFIC OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 100 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 101 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 102 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 103 CHINA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 104 CHINA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 105 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 106 CHINA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 107 CHINA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 108 CHINA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 109 CHINA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)
TABLE 110 CHINA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 111 CHINA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 112 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 113 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 114 UDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 115 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 116 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 117 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 118 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 119 CHINA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 120 CHINA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 121 CHINA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 122 CHINA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 123 CHINA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 124 CHINA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 125 CHINA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 126 CHINA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 127 CHINA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 128 CHINA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 129 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 130 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 131 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 132 INDIA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 133 INDIA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 134 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 135 INDIA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 136 INDIA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 137 INDIA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 138 INDIA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)
TABLE 139 INDIA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 140 INDIA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 141 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 142 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 143 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 144 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 145 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 146 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 147 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 148 INDIA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 149 INDIA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 150 INDIA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 151 INDIA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 152 INDIA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 153 INDIA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 154 INDIA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 155 INDIA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 156 INDIA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 157 INDIA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 158 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 159 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 160 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 161 JAPAN TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 162 JAPAN TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 163 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 164 JAPAN SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 165 JAPAN TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 166 JAPAN PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 167 JAPAN MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)
TABLE 168 JAPAN CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 169 JAPAN EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 170 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 171 AE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 172 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 173 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 174 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 175 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 176 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 177 JAPAN CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 178 JAPAN CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 179 JAPAN ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 180 JAPAN GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 181 JAPAN PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 182 JAPAN ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 183 JAPAN NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 184 JAPAN ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 185 JAPAN OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 186 JAPAN OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 187 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 188 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 189 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 190 AUSTRALIA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 191 AUSTRALIA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 192 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 193 AUSTRALIA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 194 AUSTRALIA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 195 AUSTRALIA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 196 AUSTRALIA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)
TABLE 197 AUSTRALIA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 198 AUSTRALIA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 199 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 200 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 201 ISREAL ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 202 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 203 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 204 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 205 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 206 AUSTRALIA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 207 AUSTRALIA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 208 AUSTRALIA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 209 AUSTRALIA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 210 AUSTRALIA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 211 AUSTRALIA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 212 AUSTRALIA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 213 AUSTRALIA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 214 AUSTRALIA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 215 AUSTRALIA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 216 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 217 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 218 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 219 SOUTH KOREA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 220 SOUTH KOREA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 221 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 222 SOUTH KOREA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 223 SOUTH KOREA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 224 SOUTH KOREA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 225 SOUTH KOREA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)
TABLE 226 SOUTH KOREA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 227 SOUTH KOREA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 228 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 229 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 230 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 231 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 232 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 233 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 234 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 235 SOUTH KOREA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 236 SOUTH KOREA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 237 SOUTH KOREA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 238 SOUTH KOREA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 239 SOUTH KOREA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 240 SOUTH KOREA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 241 SOUTH KOREA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 242 SOUTH KOREA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 243 SOUTH KOREA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 244 SOUTH KOREA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 245 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 246 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 247 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 248 SINGAPORE TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 249 SINGAPORE TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 250 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 251 SINGAPORE SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 252 SINGAPORE TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 253 SINGAPORE PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 254 SINGAPORE MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)
TABLE 255 SINGAPORE CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 256 SINGAPORE EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 257 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 258 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 259 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 260 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 261 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 262 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 263 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 264 SINGAPORE CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 265 SINGAPORE CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 266 SINGAPORE ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 267 SINGAPORE GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 268 SINGAPORE PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 269 SINGAPORE ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 270 SINGAPORE NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 271 SINGAPORE ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 272 SINGAPORE OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 273 SINGAPORE OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 274 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 275 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 276 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 277 MALAYSIA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 278 MALAYSIA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 279 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 280 MALAYSIA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 281 MALAYSIA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 282 MALAYSIA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 283 MALAYSIA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)
TABLE 284 MALAYSIA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 285 MALAYSIA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 286 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 287 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 288 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 289 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 290 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 291 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 292 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 293 MALAYSIA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 294 MALAYSIA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 295 MALAYSIA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 296 MALAYSIA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 297 MALAYSIA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 298 MALAYSIA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 299 MALAYSIA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 300 MALAYSIA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 301 MALAYSIA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 302 MALAYSIA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 303 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 304 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 305 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 306 THAILAND TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 307 THAILAND TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 308 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 309 THAILAND SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 310 THAILAND TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 311 THAILAND PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 312 THAILAND MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)
TABLE 313 THAILAND CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 314 THAILAND EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 315 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 316 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 317 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 318 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 319 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 320 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 321 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 322 THAILAND CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 323 THAILAND CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 324 THAILAND ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 325 THAILAND GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 326 THAILAND PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 327 THAILAND ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 328 THAILAND NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 329 THAILAND ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 330 THAILAND OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 331 THAILAND OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 332 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 333 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 334 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 335 INDONESIA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 336 INDONESIA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 337 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 338 INDONESIA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 339 INDONESIA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 340 INDONESIA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 341 INDONESIA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)
TABLE 342 INDONESIA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 343 INDONESIA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 344 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 345 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 346 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 347 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 348 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 349 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 350 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 351 INDONESIA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 352 INDONESIA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 353 INDONESIA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 354 INDONESIA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 355 INDONESIA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 356 INDONESIA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 357 INDONESIA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 358 INDONESIA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 359 INDONESIA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 360 INDONESIA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 361 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 362 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 363 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 364 PHILIPPINES TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 365 PHILIPPINES TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 366 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 367 PHILIPPINES SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 368 PHILIPPINES TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 369 PHILIPPINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 370 PHILIPPINES MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)
TABLE 371 PHILIPPINES CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 372 PHILIPPINES EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 373 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 374 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 375 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 376 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 377 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 378 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 379 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 380 PHILIPPINES CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 381 PHILIPPINES CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 382 PHILIPPINES ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 383 PHILIPPINES GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 384 PHILIPPINES PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 385 PHILIPPINES ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 386 PHILIPPINES NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 387 PHILIPPINES ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 388 PHILIPPINES OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 389 PHILIPPINES OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 390 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 391 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 392 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 393 VIETNAM TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 394 VIETNAM TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 395 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 396 VIETNAM SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 397 VIETNAM TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 398 VIETNAM PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 399 VIETNAM MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)
TABLE 400 VIETNAM CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 401 VIETNAM EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 402 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 403 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 404 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 405 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 406 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 407 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 408 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 409 VIETNAM CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 410 VIETNAM CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 411 VIETNAM ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 412 VIETNAM GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 413 VIETNAM PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 414 VIETNAM ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 415 VIETNAM NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 416 VIETNAM ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 417 VIETNAM OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 418 VIETNAM OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 419 REST OF ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
图片列表
FIGURE 1 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: MARKET TYPE OF MANUFACTURER COVERAGE GRID
FIGURE 11 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: SEGMENTATION
FIGURE 12 UTILIZATION OF ADVANCED TECHNOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS MANUFACTURING IS DRIVING THE ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 SMALL MOLECULE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET
FIGURE 15 NUMBER OF PERSONS AGED 60 YEARS ACROSS SEVERAL REGIONS IN 2017 AND 2050
FIGURE 16 HEALTHCARE EXPENDITURE PER CAPITA
FIGURE 17 SHARE OF API MARKET OCCUPIED IN ASIA
FIGURE 18 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, 2021
FIGURE 19 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, 2017-2028 (USD MILLION)
FIGURE 20 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, CAGR (2021-2028)
FIGURE 21 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, LIFELINE CURVE
FIGURE 1 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, 2021
FIGURE 2 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, 2017-2028 (USD MILLION)
FIGURE 3 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 4 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, LIFELINE CURVE
FIGURE 5 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURERS, 2021
FIGURE 6 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURERS, 2017-2028 (USD MILLION)
FIGURE 7 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURERS, CAGR (2021-2028)
FIGURE 8 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURERS, LIFELINE CURVE
FIGURE 9 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, 2021
FIGURE 10 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, 2017-2028 (USD MILLION)
FIGURE 11 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, CAGR (2021-2028)
FIGURE 12 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, LIFELINE CURVE
FIGURE 13 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY CHEMICAL SYNTHESIS, 2021
FIGURE 14 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
FIGURE 15 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY CHEMICAL SYNTHESIS, CAGR (2021-2028)
FIGURE 16 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY CHEMICAL SYNTHESIS, LIFELINE CURVE
FIGURE 17 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG, 2021
FIGURE 18 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG, 2017-2028 (USD MILLION)
FIGURE 19 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG, CAGR (2021-2028)
FIGURE 20 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG, LIFELINE CURVE
FIGURE 21 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY USAGE, 2021
FIGURE 22 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY USAGE, 2017-2028 (USD MILLION)
FIGURE 23 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY USAGE, CAGR (2021-2028)
FIGURE 24 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY USAGE, LIFELINE CURVE
FIGURE 25 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, 2021
FIGURE 26 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, 2017-2028 (USD MILLION)
FIGURE 27 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, CAGR (2021-2028)
FIGURE 28 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, LIFELINE CURVE
FIGURE 29 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC APPLICATION, 2021
FIGURE 30 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
FIGURE 31 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC APPLICATION, CAGR (2021-2028)
FIGURE 32 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC APPLICATION, LIFELINE CURVE
FIGURE 33 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: SNAPSHOT (2020)
FIGURE 34 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY COUNTRY (2020)
FIGURE 35 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 36 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 37 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE (2021-2028)
FIGURE 38 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: COMPANY SHARE 2020 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
